Savara Inc (SVRA) Stock Price, Quote & News

Company Profile

Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company was founded in 2007 and is headquartered in Langhorne, Pennsylvania.

Industry: Biotechnology

Sector: Healthcare

Phone: 512 614 1848

Website: www.savarapharma.com

Address:

1717 Langhorne Newtown Road, Suite 300, Langhorne, United States

Flydown Mar. 20 at 8:22 PM

$SVRA volume 9 milioni!

0 · Reply

art62 Mar. 19 at 4:48 PM

$SVRA Adding ...good risk reward

1 · Reply

Vavavoom Mar. 18 at 1:11 AM

$SVRA hmmm

0 · Reply

ghostdemon Mar. 17 at 8:45 PM

$SVRA PnD scam

0 · Reply

Richterscale Mar. 17 at 7:58 PM

$SVRA I read they signed a long term lease agreement to move Headquarters. 5 year lease

2 · Reply

Flydown Mar. 17 at 6:11 PM

$SVRA volume will go over 2M$ also today!

0 · Reply

Flydown Mar. 17 at 5:58 PM

$SVRA preparing shorts squeeze!

1 · Reply

Richterscale Mar. 17 at 5:03 PM

$SVRA I might DCA a little more but I don’t need to get stupid either.

0 · Reply

Spacemonkey1 Mar. 17 at 4:22 PM

$SVRA now’s a good time to buy more, this may be around the lowest it gets for a while

0 · Reply

Spacemonkey1 Mar. 17 at 4:19 PM

$SVRA all these puts at 5….

0 · Reply

Savara Reports Fourth Quarter and Year End 2025 Financial Results and Provides Business Update

Mar 6, 2026, 4:05 PM EST - 15 days ago

Savara Provides Regulatory Update on the MOLBREEVI* Development Program in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)

Mar 4, 2026, 4:05 PM EST - 17 days ago

Savara Announces Participation in 2026 Citizens Life Sciences Conference

Feb 20, 2026, 4:15 PM EST - 4 weeks ago

Savara Announces the U.S. Food and Drug Administration (FDA) Filed the MOLBREEVI* Biologics License Application (BLA) in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)

Feb 13, 2026, 4:05 PM EST - 5 weeks ago

Savara Announces New Employment Inducement Grant

Feb 4, 2026, 4:05 PM EST - 6 weeks ago

Savara Announces Participation in Upcoming Investor Healthcare Conferences

Jan 27, 2026, 8:05 AM EST - 7 weeks ago

Savara Announces Amendment to Hercules Capital Debt Facility Providing up to $75M of Additional Debt Funding Upon U.S. Food and Drug Administration (FDA) Approval of MOLBREEVI*

HTGC

Jan 15, 2026, 5:16 AM EST - 2 months ago

Savara Inc. (SVRA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 8, 2026, 4:05 PM EST - 2 months ago

PANTHERx® Rare Selected by Savara as the U.S. Exclusive Specialty Pharmacy for MOLBREEVI*

Dec 22, 2025, 8:30 AM EST - 3 months ago

Savara Resubmits the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* for the Potential Treatment of Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)

Dec 17, 2025, 8:05 AM EST - 3 months ago

Savara Announces Participation in the 44th Annual J.P. Morgan Healthcare Conference

Dec 11, 2025, 8:05 AM EST - 3 months ago

Savara Announces European Patent Office (EPO) Intends to Grant a Patent for the Liquid Formulation of MOLBREEVI*

Dec 2, 2025, 8:05 AM EST - 3 months ago

Savara and PARI Granted a European Patent Covering the Drug-Device Combination of MOLBREEVI* Delivered Via the Proprietary eFlow® Nebulizer System

Nov 16, 2025, 6:35 AM EST - 4 months ago

Savara: A High-Risk Opportunity

Nov 12, 2025, 4:05 PM EST - 4 months ago

Savara Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 5, 2025, 5:54 PM EST - 4 months ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of November 7, 2025 in Savara Inc. Lawsuit – SVRA

Oct 31, 2025, 4:05 PM EDT - 5 months ago

Savara Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Total Gross Proceeds of $149.5M

Oct 30, 2025, 11:05 AM EDT - 5 months ago

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Savara

Oct 29, 2025, 9:43 PM EDT - 5 months ago

Savara Announces Pricing of $130.0 Million Public Offering of Common Stock and Pre-funded Warrants

Oct 29, 2025, 4:07 PM EDT - 5 months ago

Savara Announces Proposed Public Offering

Oct 29, 2025, 4:01 PM EDT - 5 months ago

Savara announces $75M Royalty Funding Agreement with RTW to Support the Potential Launch of MOLBREEVI* in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)

Oct 28, 2025, 9:58 AM EDT - 5 months ago

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Savara

Oct 23, 2025, 1:36 PM EDT - 5 months ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Savara

Oct 17, 2025, 8:05 AM EDT - 5 months ago

Savara Announces Chief Medical Officer (CMO) Transition

Oct 14, 2025, 12:14 PM EDT - 5 months ago

SAVARA DEADLINE REMINDER: Bragar Eagel & Squire, P.C. Reminds Savara Investors to Contact the Firm Before the November 7th Deadline

Oct 12, 2025, 8:44 AM EDT - 5 months ago

SVRA INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Savara

Oct 9, 2025, 7:42 AM EDT - 5 months ago

Savara: Back On Track With Upcoming APAP BLA Filing

Oct 6, 2025, 8:45 AM EDT - 5 months ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of November 7, 2025 in Savara Inc. Lawsuit - SVRA

Oct 2, 2025, 4:05 PM EDT - 6 months ago

Savara Announces Encore Presentations of Results From the Phase 3 IMPALA-2 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at CHEST 2025

Sep 29, 2025, 2:00 AM EDT - 6 months ago

Savara Presents New Data From the Phase 3 IMPALA-2 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the European Respiratory Society (ERS) Congress 2025

Sep 2, 2025, 9:00 AM EDT - 7 months ago

Savara Announces New U.S. Health Claims Data Analysis Finds Over 50% Increase in the Estimated Number of Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) Patients Compared to Previous Claims Analysis

Aug 20, 2025, 5:15 PM EDT - 7 months ago

New England Journal of Medicine (NEJM) to Publish Results From Savara's Pivotal Phase 3 IMPALA-2 Clinical Trial in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)

Aug 18, 2025, 8:05 AM EDT - 7 months ago

Savara to Present New Data from the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the European Respiratory Society Congress 2025

Aug 13, 2025, 8:05 AM EDT - 7 months ago

Savara Reports Second Quarter 2025 Financial Results and Provides a Business Update

Flydown Mar. 20 at 8:22 PM

$SVRA volume 9 milioni!

0 · Reply

art62 Mar. 19 at 4:48 PM

$SVRA Adding ...good risk reward

1 · Reply

Vavavoom Mar. 18 at 1:11 AM

$SVRA hmmm

0 · Reply

ghostdemon Mar. 17 at 8:45 PM

$SVRA PnD scam

0 · Reply

Richterscale Mar. 17 at 7:58 PM

$SVRA I read they signed a long term lease agreement to move Headquarters. 5 year lease

2 · Reply

Flydown Mar. 17 at 6:11 PM

$SVRA volume will go over 2M$ also today!

0 · Reply

Flydown Mar. 17 at 5:58 PM

$SVRA preparing shorts squeeze!

1 · Reply

Richterscale Mar. 17 at 5:03 PM

$SVRA I might DCA a little more but I don’t need to get stupid either.

0 · Reply

Spacemonkey1 Mar. 17 at 4:22 PM

$SVRA now’s a good time to buy more, this may be around the lowest it gets for a while

0 · Reply

Spacemonkey1 Mar. 17 at 4:19 PM

$SVRA all these puts at 5….

0 · Reply

Spacemonkey1 Mar. 17 at 4:16 PM

$SVRA 3 days and then pop

0 · Reply

Richterscale Mar. 16 at 6:56 PM

$SVRA IMO it gets a merger or buyout.

0 · Reply

StreetwiseReports Mar. 16 at 6:43 PM

Langhorne, PA Biotech Eyes Mid-2026 Molbreevi Launch https://ow.ly/PFml50YuXaM H.C. Wainwright reiterated its rating and price target on Savara Inc. ($SVRA:NASDAQ), citing a cleared regulatory path for Molbreevi with an August 22, 2026, PDUFA date, no planned FDA Advisory Committee, and accelerating commercial preparations targeting 1,700 accounts and 4,500 healthcare professionals ahead of a potential approval in the rare autoimmune PAP market.

0 · Reply

ckruel Mar. 16 at 4:22 PM

$SVRA https://tipranks.onelink.me/WJho/0wis4ym9 Another analyst target

0 · Reply

ckruel Mar. 16 at 1:24 PM

$SVRA He also underscores the parallel progress ex-U.S., with marketing applications now submitted to both the EMA and the U.K. regulator, positioning the drug for broader international uptake and reinforcing its commercial potential. Coupled with Savara’s solid balance sheet, current cash of roughly $236 million, and access to substantial non-dilutive capital upon approval, he views the company as well funded for launch execution and maintains an Outperform rating with meaningful upside to his $11 price target.

0 · Reply

ckruel Mar. 16 at 1:24 PM

$SVRA Francois Brisebois has given his Buy rating due to a combination of factors tied to Savara’s lead asset, MOLBREEVI, and its regulatory momentum. He highlights the recent FDA Day 74 letter confirming no advisory committee and ongoing priority review of the BLA, alongside strong Phase 3 data showing statistically significant and durable efficacy in aPAP, which together underpin his high confidence in U.S. approval by the August 22, 2026 PDUFA date.

0 · Reply

ckruel Mar. 16 at 1:22 PM

$SVRA Savara, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Francois Brisebois from LifeSci Capital reiterated a Buy rating on the stock and has a $11.00 price target.

0 · Reply

BioGem Mar. 14 at 11:46 PM

$SVRA Shortable above $5, many critical negatives. Accounting for the additional 48.6M vested pre-funded warrants the outstanding shares are near 254M and a mkt cap at 1.35B. Extremely expensive: -Bottom line and operating losses are accelerating already. -Costs will skyrocket in H2 26 when they build a marketing and sales team. -Expect to run out of cash and raise funds through expensive debt with covenants. -Adoption will be slow for several quarters into late 2027, including insurance coverage dragging on. -Stock options and RSU are all deep in the money and will dilute hugely the shares o/s. -No prestigious biotech fund is invested. -Short ratio is huge = consensus of poor performance.

4 · Reply

art62 Mar. 13 at 3:34 PM

$SVRA so he sees a double from here

0 · Reply

art62 Mar. 13 at 3:32 PM

$SVRA ATsai Jefferiies "We remain 90%+ confident in the US approval of Molbreevi (inhaled GM-CSF) in aPAP rare lung disease by Aug 22, 2026 PDUFA ($500M+ oppty). With mgmt's patient-finding efforts providing line of sight to 1000+ patients, we foresee an initial bolus shortly after a pot'l Sep 2026 launch. Notably, mgmt sounds comfortable with the first twelve-month cons of $70-80M. Net-net, $500M sales x 4-5x multiple (biosimilars are unlikely) = $2.0-2.5B valuation (vs $1.2B cap)."

0 · Reply

Flydown Mar. 13 at 7:29 AM

$SVRA a lot patience!

0 · Reply

Richterscale Mar. 10 at 6:59 PM

$SVRA Bots now trolls. Some actual activity! Lol

0 · Reply

Market Cap	1.02B
Revenue (ttm)	0.00
Net Income (ttm)	-118.84M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	9,317,300
Avg Vol	1,644,042
Day's Range	N/A - N/A
Shares Out	204.66M
Stochastic %K	8%
Beta	0.31
Analysts	Strong Sell
Price Target	$10.81